A Randomized Phase 3 Study Comparing <scp>P2B001</scp> to its Components (Low‐Dose Extended‐Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended‐Release Pramipexole in Early Parkinson's Disease
C. Warren Olanow(Icahn School of Medicine at Mount Sinai), Lawrence Elmer(University of Toledo), David Kreitzman(Centre for Movement Disorders), Andrew McGarry(Cooper Medical School of Rowan University), Ramon Gil(Centre for Movement Disorders), Karl Kieburtz(Beth Israel Deaconess Medical Center), Daniel J. Burdick, Robert A. Hauser(University of South Florida), Rohit Dhall(University of Arkansas for Medical Sciences), Joy Antonelle de Marcaida(Centre for Movement Disorders)
Cited by 5
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k
MDS research criteria for prodromal Parkinson's disease
|Movement Disorders|2015|1.3k
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
|New England Journal of Medicine|2009|889
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
|Movement Disorders|2017|846